Log In
Print
BCIQ
Print
Print this Print this
 

OBI-822/821 (formerly OPT-822/821)

  Manage Alerts
Collapse Summary General Information
Company OBI Pharma Inc.
DescriptionSynthetic glycoprotein composed of Globo H conjugated to keyhole limpet hemocyanin (KLH), and co-administered with the saponin-based adjuvant OBI-821
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityActive immunotherapy

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today